Yoshioka 2018.

Study characteristics
Study design	Cohort
Study setting	Setting: Chiba University Hospital Country: Japan Dates: NR
Selection of participants	People under a protocol approved by the Ethics Committee of the Chiba University Graduate School of Medicine, with informed consent obtained from the people or their guardians
Participant characteristics	Sample size: 84 (deaths: NR) Age: median NR; aged < 60 years: 36 (43%); aged ≥ 60 years: 48 (57%) Sex: 51% men KPS: median NR; KPS ≤ 70: 47 (56%); KPS > 70: 37 (44%)
Tumour characteristics	GBM: 100% First diagnosis: NR Biopsy: NR; subtotal resection: 0.57%; total resection: 0.43% IDH1 wild‐type: 94%; IDH2 wild‐type: NR
Treatment regimen	Stupp protocol
MGMT promoter methylation tests implemented	MSP
Dates and follow‐up	Timing of MGMT assessment: time of the first surgery Start time for follow‐up: date of initial surgery; follow‐up: median NR; range NR
Notes

DIF: double immunofluorescence; ECOG: Eastern Cooperative Oncology Group; FFPE: formalin‐fixed paraffin‐embedded; FSQ‐MS‐PCR: fluorescent semi‐quantitative methylation‐specific polymerase chain reaction; GBM: glioblastoma; IDH: isocitrate dehydrogenase; IHC: immunohistochemistry; KPS: Karnofsky performance status; MGMT: O⁶‐methylguanine–DNA methyltransferase; mRNA: messenger ribonucleic acid; MRI: magnetic resonance imaging; MS‐MLPA: methylation‐specific multiplex ligation‐dependent probe amplification; MS‐RE‐qPCR: methylation‐specific restriction enzyme quantitative polymerase chain reaction; MSP: methylation‐specific polymerase chain reaction; n: number of participants; NR: not reported; PCR: polymerase chain reaction; PCR‐HRM: polymerase chain reaction with high‐resolution melting; PCR‐mRNA: polymerase chain reaction‐messenger ribonucleic acid; PCV: procarbazine plus lomustine plus vincristine; PSQ: pyrosequencing; QF‐IHC: quantitative fluorescence immunohistochemistry; qMSP: quantitative methylation‐specific polymerase chain reaction; qMSP‐PSQ: quantitative methylation‐specific polymerase chain reaction with pyrosequencing; RCT: randomised controlled trial; RNA: ribonucleic acid; SD: standard deviation; SQ‐MSP: semi‐quantitative methylation‐specific polymerase chain reaction; TMZ: temozolomide; WHO: World Health Organization.